Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Ralph Pagano

Neurology Phoenix, AZ Medical Doctor

NPI 1902846181 CMS profile 313841

3815 E Bell Rd, Ste 2400, Phoenix, AZ 85032

Open in the dashboard

General payments

$5,198

352 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Ralph Pagano of Phoenix, AZ is reported in the CMS Open Payments database as having received $5,198 across 352 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $183 12
2022 General $341 19
2021 General $1,536 105
2020 General $1,685 116
2019 General $1,452 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ralph Pagano
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ralph Pagano were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ralph Pagano Neurology median Middle half National median
2019 $1,452 $474 $118–$2,177 $163
2020 $1,685 $367 $82–$2,309 $114
2021 $1,536 $438 $104–$2,547 $132
2022 $341 $442 $103–$2,388 $149
2023 $183 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. UCB, Inc. $608 46 payments
  2. ACADIA Pharmaceuticals Inc $406 30 payments
  3. Novartis Pharmaceuticals Corporation $348 24 payments
  4. Upsher-Smith Laboratories LLC $326 26 payments
  5. AbbVie, Inc. $315 25 payments
  6. Allergan Inc. $310 27 payments
  7. Alexion Pharmaceuticals, Inc. $295 17 payments
  8. Teva Pharmaceuticals USA, Inc. $272 22 payments
  9. Amneal Pharmaceuticals LLC $252 15 payments
  10. Abbott Laboratories $234 12 payments
  11. Other $1,831 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,076 343 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $121 8 payments
  3. Education $1 1 payment
Products named General payments · program years 2019–2023
  1. Briviact $412 26 payments
  2. NUPLAZID $371 28 payments
  3. Soliris $295 17 payments
  4. RYTARY $252 15 payments
  5. AJOVY $238 19 payments
  6. AIMOVIG $237 13 payments
  7. BOTOX $236 20 payments
  8. MAYZENT $219 16 payments
  9. Neupro $197 20 payments
  10. Zembrace SymTouch Sumatriptan Injection $191 13 payments
  11. Other $3,402 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

352 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record